MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

12.59 3.62

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.22

Max

12.82

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1M -16M
Darbuotojai	54
EBITDA	-1.2M -18M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+23.7% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	57M 640M
Ankstesnė atidarymo kaina	8.97
Ankstesnė uždarymo kaina	12.59

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-07 17:26; UTC

Svarbiausios naujienos

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026-04-07 23:55; UTC

Rinkos pokalbiai

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026-04-07 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Market Talk Roundup: Latest on U.S. Politics

2026-04-07 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026-04-07 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026-04-07 23:42; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-07 23:42; UTC

Rinkos pokalbiai

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026-04-07 23:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026-04-07 23:15; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026-04-07 23:04; UTC

Svarbiausios naujienos

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026-04-07 23:04; UTC

Svarbiausios naujienos

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026-04-07 23:03; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-07 23:03; UTC

Rinkos pokalbiai

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026-04-07 23:01; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026-04-07 22:58; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026-04-07 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026-04-07 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-07 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-07 19:45; UTC

Rinkos pokalbiai

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026-04-07 19:17; UTC

Svarbiausios naujienos

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026-04-07 19:16; UTC

Rinkos pokalbiai

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026-04-07 19:07; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026-04-07 18:41; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026-04-07 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026-04-07 18:39; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026-04-07 18:24; UTC

Svarbiausios naujienos

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026-04-07 17:08; UTC

Rinkos pokalbiai

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026-04-07 16:21; UTC

Svarbiausios naujienos

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026-04-07 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

23.7% į viršų

12 mėnesių prognozė

Vidutinis 15.5 USD 23.7%

Aukščiausias 18 USD

Žemiausias 14 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.